Currently out of the existing stock ratings of Andreas Argyrides, 96 are a BUY (82.05%), 16 are a HOLD (13.68%), 5 are a SELL (4.27%).

Andreas Argyrides

Work Performance Price Targets & Ratings Chart

Analyst Andreas Argyrides, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 34.22% that have a potential upside of 50.5% achieved within 125 days. Previously, Andreas Argyrides worked at WEDBUSH.

Andreas Argyrides’s has documented 231 price targets and ratings displayed on 30 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on DYN, Dyne Therapeutics  at 09-Oct-2025.

Wall Street Analyst Andreas Argyrides

Analyst best performing recommendations are on MNPR (MONOPAR THERAPEUTICS).
The best stock recommendation documented was for MNPR (MONOPAR THERAPEUTICS) at 9/3/2025. The price target of $77 was fulfilled within 22 days with a profit of $40.79 (112.65%) receiving and performance score of 51.2.

Average potential price target upside

RGNX Regenxbio UBX Unity Biotechnology ALBO Albireo Pharma ASND Ascendis Pharma AS BMRN Biomarin Pharmaceutical AQST Aquestive Therapeutics SGMO Sangamo Therapeutics AVTE Aerovate Therapeutics KALA Kala Pharmaceuticals UTHR United Therapeutics VRNA Verona Pharma PLC ADR GBT Global Blood Therapeutics GOSS Gossamer Bio IMUX Immunic KROS Keros Therapeutics  LQDA Liquidia Technologies MLTX MoonLake Immunotherapeutics RANI Rani Therapeutics Holdings PCRX Pacira Pharmaceuticals SRPT Sarepta Therapeutics CLSD Clearside Biomedical OCS Oculis Holding AG Ordinary shares SPRY ARS Pharmaceuticals ABEO Abeona Therapeutics BNTC Benitec Biopharma Ltd ADR DYN Dyne Therapeutics  IFRX InflaRx N.V. LRMR Larimar Therapeutics MNKD MannKind Corp MNPR Monopar Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$34

$22.27 (189.86%)

$34

1 months 12 days ago
(07-Sep-2025)

0/11 (0%)

$24.52 (258.65%)

Buy

1 months 12 days ago
(07-Sep-2025)

0/6 (0%)

$28.77 (123.85%)

Hold

$12

$0.27 (2.30%)

$14

6 months 3 days ago
(16-Apr-2025)

1/3 (33.33%)

$6.06 (102.02%)

174

Buy

$25

$13.27 (113.13%)

$30

6 months 17 days ago
(02-Apr-2025)

4/14 (28.57%)

$18.33 (274.81%)

50

Buy

$24

$12.27 (104.60%)

$22

7 months 6 days ago
(13-Mar-2025)

0/2 (0%)

$17.28 (257.14%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Andreas Argyrides is most bullish on?

Potential upside of $141.66 has been obtained for UTHR (UNITED THERAPEUTICS)

Which stock is Andreas Argyrides is most reserved on?

Potential downside of -$9.48 has been obtained for LQDA (LIQUIDIA TECHNOLOGIES)

What Year was the first public recommendation made by Andreas Argyrides?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?